Sweetser Lab

Research topics include: leukemia, tumor suppressor gene, cancer genetics, stem cell, targeted therapy.


David Sweetser, MD, PhD
Assistant Professor of Pediatrics
Massachusetts General Hospital for Children Cancer Center

Assistant Professor of Pediatrics
Harvard Medical School

Research Summary

The Sweetser laboratory investigates how leukemia and other cancers develop with the goal of developing novel, safer, and more effective therapies. We are investigating how the Groucho/TLE family of co-repressors function as potent tumor suppressors of acute myeloid leukemia and their roles in normal development and cell function. Knock-out mice for Tle1 and Tle4 have identified critical roles for these proteins in hematopoiesis, bone, lung, and brain development, as well as a critical role in limiting inflammation. In collaboration with Jing-Ruey Yeh, PhD at Massachusetts General Hospital we are using the zebrafish as a model for cancer development and drug discovery. The laboratory is also using whole exome sequencing to characterize underlying cancer predisposition genes in patients with a variety of pediatric malignancies. As the MGH site director for the newly established HMS Undiagnosed Diseases Center, Dr. Sweetser is also leading a group of clinicians and researchers actively engaged in elucidating the underlying basis of a wide variety of human diseases.

Read the Sweetser Lab's Annual report in full

Group Members

David Sweetser, MD, PhD
Principal Investigator

Group Members

  • Selvi Ramasamy, PhD
  • Thomas Shin
  • Rae'e Yamin

Research Projects

Genetics of Acute Myeloid Leukemia

Our laboratory is working to elucidate cooperating networks underlying leukemogenesis and to help develop novel targeted therapies for cancer. Current projects are detailed below.

Evaluation of the role of the Groucho/ TLE family of corepressors in development and leukemogenesis.

Our laboratory has defined TLE1 and TLE4 as members of a novel family of tumor suppressor genes, the TLE/Groucho proteins, the inactivation of which appears to be a key cooperating event with other oncogenes in the development of a subset of acute myeloid leukemias.

The Groucho/TLE family of corepressor proteins is known to modulate many of the major pathways involved in development and oncogenesis, including Wnt/β-catenin, Notch, Myc, NFκB, and TGFβ. However, researchers are only beginning to understand their potential role in oncogenesis. These genes appear to behave as tumor suppressor genes in the pathogenesis of other myeloid malignancies and lymphomas. However, the role of this gene family in malignancies is complex, as in synovial cell sarcoma where TLE1 is over-expressed and behaves as an oncogene by pairing with the SS18-SSX fusion oncogene and ATF2 to silence other tumor suppressor genes. Current work in the lab seeks to clarify the role these proteins play in malignancy as well as in normal development. We have shown these proteins potently regulate Myc leukemogenesis as demonstrated in both murine and zebrafish models of leukemia. In addition, TLE1 and TLE4 are potent inhibitors of the AML1-ETO oncogene in the most common subtype of AML. The mechanism of this inhibition appears to involve both regulation of gene transcription and chromatin structure. In large part this cooperative effect appears to involve regulation of Wnt signaling and inflammatory gene pathways.

Our laboratory is also working to understand the role these proteins play in normal development. To assist in this evaluation, we have generated conditional Tle1 and Tle4 knockout mice and are currently characterizing role these proteins play in the development of a variety of tissues. Our studies to date indicate TLE1 is a potent repressor of inflammation via its ability to repress NFKB, while TLE4 is a critical modulator of neuronal and B-cell differentiation and is required for hematopoietic stem cell maintenance, as well as bone development.

Identification of novel inhibitors of  AML1-ETO

We have collaborated with the Yeh laboratory to identify several novel small molecule inhibitors of AML1-ETO using a zebrafish high-throughput biological screen. Our results, published in early 2012, identified several classes of agents capable of inhibiting AML1-ETO, and we have demonstrated the efficacy of these agents in treating mouse models of leukemia.

Identifying Genetic Predispositions to Cancer

It is being increasingly recognized that genetic predispositions play a role in the development of many cancers, especially those in children. We are using whole exome sequencing of several cancer types in children to help identify germline mutations that can influence cancer development. Individuals with these mutations may be at higher risk for relapse or the development of additional cancers, and warrant more intensive and extensive surveillance.

The Undiagnosed Diseases Network

The Harvard Medical School hospital consortium of MGH, Brigham and Women’s Hospital and Children’s Hospital has been recently selected as one of six new sites comprising a nationwide Undiagnosed Diseases Network. As Chief of Medical Genetics at MGH, and the MGH site director for the UDN, Dr. Sweetser is coordinating a team of expert clinicians and researchers, and is using whole exome and whole genome sequencing, and a variety of investigative resources to identify the underlying basis of a variety of challenging human diseases.


View a list of publications by researchers at the Sweetser Laboratory

Selected Publications

Giampietro, PF, Armstrong L, Stoddard A, Blank RD, Livingston J, Raggio CL, Rasmussen K, Pickart M, Lorier R, Turner A, Sund S, Sobrera N, Neptune E, Sweetser DA, Santiago-Cornier A, Broeckel, U. Whole Exome Sequenc-ing Identifies a POLRID Mutation Segregating in a Father and Two Daughters with Findings of Klippel- Feil and Treacher Collins Syndromes, Am J Med Genet, 167:95-102, 2015.

Wheat JC, Krause DS, Shin TH, Chen X, Wang J, Ding D, Yamin R, Sweetser DA. The Corepressor Tle4 is a Novel Regulator of Murine Hemato-poiesis and Bone Development, PLOS One, 9:e105557, 2014.

Zhang Y, Wang J, Wheat J, Chen X, Jin S, Sadrzadeh H, Fathi AT, Peterson RT, Kung AL, Sweetser DA, Yeh JR. AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/beta-catenin signaling pathway. Blood, 121:4906-4916, 2013.

Yeh JR, Munson K, Alagib K, Goldfarb A, Sweetser DA. Discovering chemi-cal modifiers of oncogene-regulated hematopoietic differentiation. Nat Chem Biol. 5:236-243, 2009.

Dayyani F, Wang J, Yeh JR, Ahn EY, Tobey E, Zhang DE, Bernstein ID, Peterson RT, Sweetser DA. Loss of TLE1 and TLE4 from the del(9q) common-ly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival. Blood. 111:4338-4347, 2008.

Sweetser DA, Peniket AJ, Haaland C, Blomberg AA, Zhang Y, Zaidi ST, Dayyani F, Zhao Z, Heerema NA, Boultwood J, Dewald GW, Paietta E, Slovak ML, Willman CL, Wainscoat JS, Bernstein ID, and Daly SB. De-lineation of the minimal commonly deleted segment and identification of candidate tumor suppressor genes in del(9q) acute myeloid leukemia. Genes, Chromosomes and Cancer. 44:279-91, 2005.


Contact Us

Sweetser Laboratory

GRJ-90455 Fruit Street Boston, MA 02114

Back to Top